ADA: Presented on Sunday, June 7, 2015 12:00 PM
Skin Advanced Glycation End Products (AGE) Fluorescence Identifies Abnormal Glucose Tolerance Independent of Levels of HbA1c and Soluble Receptor for Advanced Glycation End Products (sRAGE)
Epidemiology - Clinical - Diagnosis and Screening
Presented on Sunday, June 7, 2015 12:00 PM
Author(s): BHASKARAN SAROJAM. REGIN, COIMBATORE SUBRAMANIAM. SHANTHIRANI, ABHIJIT SHINY, RAJENDRA PRADEEPA, MOHAN DEEPA, JOHN MAYNARD, RANJIT M. ANJANA, MUTHUSAMY BALASUBRAMANYAM, VISWANATHAN MOHAN, Chennai, India, Albuquerque, NM
Skin AGE fluorescence has been widely studied and linked to the development of diabetic complications. Recent studies suggest their utility in screening for abnormal glucose tolerance (AGT). Using Scout DS, a noninvasive, point-of-care (POC) diabetes screening device, we have recently demonstrated that SCOUT is an effective tool for AGT screening in Asian Indians. In this study, we evaluated the clinical utility of SCOUT in picking up AGT and analyzed its relationship with HbA1c (both by autoanalyzer and POC device) and serum levels of soluble receptor for advanced glycation end products (sRAGE). Subjects (n=139) without previous diagnosis of diabetes or impaired glucose tolerance in Chennai, India were subjected to oral glucose tolerance test (OGTT). They were classified as normal glucose tolerance (NGT) and abnormal glucose tolerance (AGT) which includes those with prediabetes or diabetes . Along with SCOUT DS score and HbA1c, circulatory levels of sRAGE were also measured by ELISA. SCOUT DS score was significantly (p<0.001) higher in subjects with AGT (52.2±6.3 AU) compared to subjects with NGT (42.5±5.3 AU). SCOUT DS score was positively correlated with BMI (r=0.404; p<0.001), fasting plasma glucose (r=0.285; p<0.001), post-prandial plasma glucose (r=0.483; p<0.001), autoanalyzer-based HbA1c (r=0.305; p<0.001) and POC-based HbA1c (r=0.341; p<0.001) and negatively correlated to sRAGE (r= -0.221; p<0.001). Logistic regression analysis revealed that the association between increased SCOUT DS score and AGT remained statistically significant (OR=1.47; p<0.001) even after adjusting for age, BMI, HbA1c and sRAGE levels. Our study underscores the clinical utility of SCOUT DS score as a non-invasive POC tool to identify the subjects at high risk for diabetes
Disclosure: B.S. Regin: None. C.S. Shanthirani: None. A. Shiny: None. R. Pradeepa: None. M. Deepa: None. J. Maynard: None. R.M. Anjana: None. M. Balasubramanyam: None. V. Mohan: None.
In this link page you can view the poster....
https://ada.apprisor.org/epsAbstractADA.cfm?id=1
or